首页> 外文期刊>Current Microbiology: An International Journal >Antibiofilm and Antimicrobial Efficacy of DispersinB(A (R))-KSL-W Peptide-Based Wound Gel Against Chronic Wound Infection Associated Bacteria
【24h】

Antibiofilm and Antimicrobial Efficacy of DispersinB(A (R))-KSL-W Peptide-Based Wound Gel Against Chronic Wound Infection Associated Bacteria

机译:DispersinB(A(R))-KSL-W肽基伤口凝胶对慢性伤口感染相关细菌的抗生物膜和抗菌功效

获取原文
获取原文并翻译 | 示例
           

摘要

The medical importance of bacterial biofilms has increased with the recognition of biofilms as one of the major contributors to the slow or non-healing chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Being a protected community of microorganisms, biofilms are notoriously refractory to antibiotic treatments. As the conventional treatment modalities have proven ineffective, this study provides the in vitro evidence to support the use of a novel combination of DispersinB(A (R)) antibiofilm enzyme that inhibits biofilm formation and disperses preformed biofilm, and thus making the biofilm bacteria more susceptible to a broad-spectrum KSL-W antimicrobial peptide. The combination of DispersinB(A (R)) and KSL-W peptide showed synergistic antibiofilm and antimicrobial activity against chronic wound infection associated biofilm-embedded bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Coagulase-negative Staphylococci (CoNS), and Acinetobacter baumannii. In addition, the wound gel formulation comprising DispersinB(A (R)), KSL-W peptide, and a gelling agent Pluronic F-127 showed a broad-spectrum and enduring antimicrobial activity against test organisms. Furthermore, as compared to commercial wound gel Silver-Sept (TM), DispersinB(A (R))-KSL-W peptide-based wound gel was significantly more effective in inhibiting the biofilm-embedded MRSA, S. epidermidis, CoNS, Vancomycin-resistant Enterococci, A. baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa (P < 0.05). Thus, this study provides promising evidence for the potential application of antibiofilm-antimicrobial DispersinB(A (R))-KSL-W wound gel in chronic wound management.
机译:随着生物膜被认为是缓慢或无法愈合的慢性伤口(如糖尿病足溃疡,下肢静脉溃疡和压疮)的主要贡献者之一,细菌生物膜的医学重要性日益提高。作为一种受保护的微生物群落,生物膜众所周知对抗生素治疗没有抵抗力。由于传统的治疗方式已被证明无效,因此本研究提供了体外证据,以支持DispersinB(A)抗生物膜酶的新型组合的使用,该酶可抑制生物膜的形成并分散预先形成的生物膜,从而使生物膜细菌更丰富。易感染广谱KSL-W抗菌肽。 DispersinB(A)和KSL-W肽的组合显示了针对慢性伤口感染相关生物膜包埋细菌如抗甲氧西林金黄色葡萄球菌(MRSA),表皮葡萄球菌,凝固酶阴性葡萄球菌(CoNS)的协同抗生物膜和抗菌活性)和鲍曼不动杆菌。另外,包含DispersinB(A),KSL-W肽和胶凝剂Pluronic F-127的伤口凝胶制剂显示出对测试生物的广谱且持久的抗微生物活性。此外,与商业伤口凝胶Silver-Sept(TM)相比,DispersinB(A)-KSL-W肽基伤口凝胶在抑制生物膜包埋的MRSA,表皮葡萄球菌,CoNS,万古霉素方面更有效耐药的肠球菌,鲍曼不动杆菌,肺炎克雷伯菌和铜绿假单胞菌(P <0.05)。因此,这项研究为抗生物膜-抗菌DispersinB(A)-KSL-W伤口凝胶在慢性伤口处理中的潜在应用提供了有希望的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号